France / CIS 66621285

VESPA CRABRO WELEDA, degré de dilution compris entre 4CH et 30CH ou entre 8DH et 60DH

granules et solution en gouttes en gouttes · orale / sublinguale

Directory source checks passedOriginal source language: French

Source data retrieved: 2026-09-17. Clinical review is not yet available.

Formgranules et solution en gouttes en gouttes
Routeorale / sublinguale
Ingredient entries1
CountryFrance

Product identity

At a glance

Authorisation holder
WELEDA
Authorisation status
Autorisation active
Market status
Commercialisée
Country
France
Source reference
CIS 66621285

Reported market status does not confirm current pharmacy stock.

From the official composition record

Ingredients & strength

Source entries are shown individually. An active substance (SA) and its reference moiety (FT) may describe the same ingredient; do not add their strengths together.

Source composition entries for VESPA CRABRO WELEDA, degré de dilution compris entre 4CH et 30CH ou entre 8DH et 60DH
IngredientStrength / referenceSource role
VESPA CRABRO POUR PRÉPARATIONS HOMÉOPATHIQUESgranules4CH à 30CH et 8DH à 60DHun compriméSAGroup 14
VESPA CRABRO POUR PRÉPARATIONS HOMÉOPATHIQUESsolution buvable en gouttes4CH à 30CH et 8DH à 60DHun compriméSAGroup 17

Pack references

Presentations (3)

1 tube(s) de 4 g

CIP13 3400930214206

Présentation active · Déclaration de commercialisation
1 flacon(s) de 30 ml

CIP13 3400930214213

Présentation active · Déclaration de commercialisation
1 flacon(s) de 60 ml

CIP13 3400930214237

Présentation active · Déclaration de commercialisation

From the French medicines authority

Official documents

The official product entry provides access to the patient leaflet and professional product information when available. Documents are in French and availability varies by medicine.

Open the official product entryBDPM · CIS 66621285 · Opens in a new tab

Check the medicine name, strength and form against your pack. The authority’s current documents may be newer than the catalogue snapshot shown here.

Where this information comes from

Sources & dates

Base de données publique des médicaments (BDPM), France. Retrieval dates record when we obtained the source files; they are not clinical review dates or a guarantee of current stock.

Source files and their retrieval dates
Source fileRetrievedSource file modified
fr_products.txtNot supplied
fr_composition.txtNot supplied
fr_packs.txtNot supplied

Directory source checks cover the factual catalogue record.Molindra clinical guidance has not yet been reviewed or published for this medicine.

Our sources and review process →